BLU-945 Monotherapy and Combination With Osimertinib in Previously Treated Patients With Advanced EGFR-Mutant (EGFRm) NSCLC in Phase 1/2 SYMPHONY Study
Y. Elamin,
M. Nagasaka,
E. Shum,
L. Bazhenova,
J. Rotow,
D.R. Spigel,
D.S.W. Tan,
A. Zalutskaya,
F. Albayya,
K.L. Reckamp
Affiliations
Y. Elamin
The University of Texas MD Anderson Cancer Center, Houston, USA
M. Nagasaka
University of California Irvine School of Medicine, Orange, USA
E. Shum
Perlmutter Cancer Center, New York University Langone Health, New York, USA
L. Bazhenova
University of California San Diego, Moores Cancer Center, San Diego, USA
J. Rotow
Dana-Farber Cancer Institute, Boston, USA
D.R. Spigel
Sarah Cannon Research Institute, Nashville, USA
D.S.W. Tan
National Cancer Centre Singapore, Singapore, Singapore
